Loading…
Loading…
Royce Micro-Cap Trust, Inc. is a closed-ended equity mutual fund launched and managed Royce & Associates, LLC. It invests in the public equity markets of the United States. The fund seeks to invest in stocks of companies operating across diversified sectors. It primarily invests in value stocks of companies with market capitalization of less than $500 million. The fund benchmarks the performance of its portfolios against Russell 2000 Index. Royce Micro-Cap Trust, Inc was formed on December 14, 1993 and is domiciled in the United States.
Is RMT's expense ratio expensive, average, or a steal for its category?
Pro reveals the verdict on a 5-tier spectrum calibrated against ICI 2025 industry averages, with strategy-aware bands so the comparison is meaningful.
Royce Micro-Cap Trust is rated a Buy, driven by strong YTD performance, a widening -12% discount, and a 6% yield likely to rise. RMT's managed distribution policy targets 7% of rolling NAV, with distributions growing alongside NAV and robust capital gains from top-performing micro-cap holdings. Micro-cap valuations remain near 25-year lows versus large caps, with small- and micro-cap earnings growth expected to outpace large caps in 2026–2027.
NAV/share declined 11.6% in 2025, but distribution coverage improved to 2.1x, and RMT outperformed its CEF category across multiple timeframes. RMT's portfolio remains diversified, with industrials and tech as top sectors and a 5.97% yield based on recent distributions. Microcap volatility and interest rate sensitivity remain key risks, but RMT has historically limited drawdowns relative to indices.
NEW YORK, June 24, 2026 /PRNewswire/ -- Average weekly trading volume of approximately 531,385 shares Fund's adviser has more than 50 years of small- and micro-cap investment experience CLOSING PRICES AS OF 05/31/26 NAV 15.73 MKT 14.04 AVERAGE ANNUAL TOTAL RETURN AS OF 05/31/26 NAV (%) MKT (%) One-Month* 6.21 6.20 Year to Date* 35.72 36.93 One-Year 70.80 73.35 Three-Year 28.50 29.82 Five-Year 11.90 11.99 10-Year 15.25 15.81 *Not Annualized Important Performance and Expense Information All performance information reflects past performance, is presented on a total return basis, net of the Fund's investment advisory fee, and reflects the reinvestment of distributions. Past performance is no guarantee of future results Current performance may be higher or lower than performance quoted.
Material Transfer Agreements provide access to leading lipid nanoparticle formulations to validate delivery of its proprietary payloads and accelerate development of in vivo Regenerative Macrophage Therapy Development programme complements Company's autologous engineered Regenerative Macrophage Therapy, RTX001, in Ph 1/2 clinical development Together, programmes aim to broaden patient population able to benefit from Regenerative Macrophage Therapy EDINBURGH, United Kingdom and LONDON, June 17, 2026 (GLOBE NEWSWIRE) -- Resolution Therapeutics Limited (“Resolution” or “Company”), a clinical-stage biopharmaceutical company pioneering Regenerative Macrophage Therapy (RMT) in inflammatory and fibrotic diseases, today announced the execution of Material Transfer Agreements with independent, best-in-class lipid nanoparticle (LNP) technology providers. Under the agreements, Resolution will conduct systematic assessments of LNP formulations for the engineering of the myeloid compartment in vivo, with preliminary results expected later this year.
Royce Micro-Cap Trust, Inc. (NYSE-RMT) declares Second Quarter Common Stock Distribution of $0.21 Per Share PR Newswire